Twitter

Invitation to live investor meeting with Chordate Medical 29 December at 14:00

On Thursday 29 December at 14:00, Chordate’s CEO Anders Weilandt will present the Company, the rationale for the Rights Issue and further information on the Company’s strategy and future plans. The presentation will be held in Swedish and will be broadcast live, hosted by Västra Hamnen Corporate Finance.

After the presentation, participants will have the opportunity to ask questions. The number of seats is limited, and the Company therefore recommends registering in advance to be assured of a seat. Registration for the investor meeting can be done via the link below.

Time: Thursday 29 December, 14:00 (2 p.m.)

Registration: https://attendee.gotowebinar.com/register/5852611762100083288

A recording of the broadcast will be available afterwards on Chordate’s website and on the Västra Hamnen Corporate Finance YouTube-kanal.

More posts

Press releases

If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.

Press releases

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). 

The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

Press releases

Chordate Medical AB

c/o Regus, Kistagången 20B
SE-164 40 Kista
Sweden

Privacy policy

Twitter